在接受TAVR治疗的左心室缩功能障碍患者的结果上,流量的影响
Besir Besir1, Shivabalan Kathavarayan Ramu1, Maryam Muhammad Ali Majeed-Saidan1
1Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, OH, USA.
概括
过导管大动脉置换 (TAVR) 在患有低梯度严重大动脉狭窄 (AS) 和左心室喷射率 (LVEF) 减少的患者中,无论流动模式如何,死亡率都相似. 这一发现对于理解这一特定患者群体的TAVR结果至关重要.
科学领域:
- 心脏病学 心脏病学
- 心脏外科手术 心脏外科手术
- 干预心脏病学 干预心脏病学
背景情况:
- 与医疗管理相比,通过导管的大动脉置换 (TAVR) 为患有经典低流低梯度 (C-LFLG AS) 和正常流低梯度 (NFLG AS) 大动脉狭窄症的患者提供了更好的结果.
- 左心室喷射分数 (LVEF) 是TAVR患者死亡率的已知预测指标.
- 基于减少LVEF的TAVR患者的流动模式的结果仍然不清楚.
研究的目的:
- 研究 LVEF 减少患者的 TAVR 结果,特别是比较 C-LFLG AS 和 NFLG AS.
- 在这些患者群体中分析TAVR后的血液动力学变化.
- 确定影响TAVR患者减少LVEF和低梯度AS的结果的因素.
主要方法:
- 一个回顾性,单中心研究包括305名患有严重AS和LVEF的患者,LVEF<50%,接受TAVR.
- 患者被分为C-LFLG AS (AV平均梯度<40 mmHg,SVI<35 mL/m2,LVEF<50%) 和低LVEF NFLG AS (AV平均梯度<40 mmHg,SVI≥35 mL/m2,LVEF<50%).
- 后勤和考克斯回归模型被用于分别确定决定因素和临床结果.
主要成果:
- 在接受TAVR的305名低LVEF患者中,NFLGAS的发病率较少 (18%).
- 在C-LFLG AS和低LVEF NFLG AS组之间,三年死亡率 (HR=1.07) 和心力衰竭再住院 (HR=1.31) 率相似.
- 末期脏病与NFLG AS相关,而糖尿病预测了C-LFLG AS.
结论:
- 在死亡率方面,TAVR结局对于患有低梯度严重AS和减少LVEF的患者来说是可比的,无论流量模式如何 (C-LFLG AS与NFLG AS).
- 该研究澄清了流动特征不会显著改变这种特定队列的TAVR后死亡风险.
相关概念视频
Mitral Stenosis I: Introduction
483
Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
483
Aortic Regurgitation III: Medical Management
399
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
399


